Bazhen Powder Veterinary Grade API is supplied as a multicomponent botanical powder for oral solid, liquid, and sterile routes. Incoming release includes laser-diffraction particle size analysis according to ISO 13320:2020 and loss-on-drying at 105°C to constant weight; material with water activity above 0.60 is not released without drying. The application profiles below are restricted to dosage forms listed in the technical dossier and do not imply regulatory approval in any specific jurisdiction.

In swine post-weaning feed mills operating under FAMI-QS 6.0 and GMP+ B1 specialty feed ingredient controls, the powder is not introduced as a direct microdose because raw botanical fibers bridge in 25–50 kg micro-ingredient hoppers. It is first pre-screened through a vibratory classifier fitted with a 60–80 mesh stainless steel sieve to remove particles above 250 µm and break up agglomerates formed during bulk storage at relative humidity above 60%. The addition ratio in complete creep and starter feed is evaluated at 0.5–1.5 wt%, equivalent to 5–15 kg/tonne; for a 10% carrier premix the powder is diluted to 100 g/kg with dried ground corncob or calcium carbonate having a validated mixing uniformity coefficient of variation not more than 5.0% under GMP+ B1. Compliance documentation is aligned to ISO 22000:2018 hazard analysis and critical control points and, where zootechnical or therapeutic statements are made, EU Regulation 2019/4 on medicated feed. Downstream production uses a two-stage preblending sequence: the powder is mixed 1:10 with carrier for 8–10 min in a vertical paddle mixer, passed through a 1.0 mm rotary screen, and then added to a 500 kg horizontal ribbon mixer at 25 rpm for 12 min. If direct addition is attempted, the density difference between the botanical powder and mineral carriers produces segregation and mixer validation failure with CV exceeding 15.0%; the preblend step avoids this. Because steam-pelleting above 75°C results in marker loss in some botanical fractions, the preferred line uses low-temperature conditioning at 60°C or post-pelleting spray application through a twin-fluid nozzle. Post-mixing loss-on-drying is maintained below 9.0% to prevent bridging in micro-dosing augers, and bagged premix is stored below 25°C with desiccant. Terminal finished product types are non-pelleted creep feed premix, mash supplementary feed, and oral granules packaged in 25 kg multi-wall paper bags with inner polyethylene liner.

What Aqueous Dispersion Limits Apply to Poultry Drinking-Water Powders?

Water-line dosing for broiler and layer flocks requires the powder to be converted into a water-dispersible powder because the native polysaccharide fraction wets poorly and settles within 10–15 min if not co-processed. The addition ratio in final drinking water is 0.1–0.3 g/L, administered for 5–7 days, but this is a formulation screening range rather than a fixed species prescription. To achieve a wetting time below 60 s, the powder is co-milled with anhydrous dextrose or spray-dried lactose in a pin mill fitted with a 0.5 mm screen to a median particle size D50 of 45–75 µm measured by ISO 13320:2020. In hard water above 250 mg/L CaCO3 total hardness, the formula includes 0.5–1.0% citric acid to prevent phenolic glycoside precipitation. The downstream process is a low-shear tumble blend at 15 rpm for 20 min in a polypropylene-lined blender, followed by nitrogen-flushed packaging into aluminum-foil/polyethylene sachets with oxygen transmission rate below 0.5 cm³/m²·24 h. In-line reconstitution is monitored by turbidity or conductivity; a stable suspension should show no visible sediment after 30 min without stirring and no pH drift outside 6.5–7.0. Compliance is evaluated by USP <711> dissolution testing in pH 6.8 aqueous buffer and microbial limits per Ph. Eur. 5.1.4 category 2A. The terminal finished product types are water-soluble powder for oral solution and oral solution stock concentrate.

Compression of the powder into ruminant oral tablets and rumen-stable boluses requires control of residual moisture because the polysaccharide-glycoside fraction plasticizes under compression at moisture above 8.0%. The addition ratio is 30–45% w/w of the core formulation per tablet or bolus, with microcrystalline cellulose and partially pregelatinized starch as diluents. Since native powder marker content can vary by ±10% across harvest batches, the formulation is normalized by assay before charging the granulator. The granulation step uses a hydroalcoholic binder containing 5.0% w/w povidone K30 in a top-spray fluid bed granulator at inlet air temperature 55–60°C, outlet air temperature 35–40°C, and final granule loss-on-drying 3.0–5.0%; granule size is retained between 150–500 µm using an in-line mill screen. Compression is performed on a 27-station rotary tablet press at 15–25 kN with precompression at 5 kN, target hardness 80–120 N, and friability below 1.0%; tablet weight uniformity is checked according to Ph. Eur. 2.9.5 and USP <905>. For a rumen-stable bolus, a second hydrophobic layer of ethylcellulose is applied in a side-vented coating pan at bed temperature 30–35°C, with coating weight gain 2.0–4.0%. The terminal finished products are oral tablets for calf and lamb drenching and prolonged-release rumen-stable boluses.

Injectable 10% Solution Sterile Filtration and Endotoxin Control

For injectable solution manufacture, the powder is processed as a native powder equivalent in Water for Injections at an addition ratio of 10% w/v. The hydration vessel is jacketed and held at 60°C for 30 min under gentle agitation, then cooled to 20–25°C before pH adjustment to 6.5–7.0 with 0.1 M sodium hydroxide or hydrochloric acid. The solution is clarified through a 0.45 µm PVDF membrane, then sterilizing-filtered through a 0.22 µm polyethersulfone cartridge. Sterile filtration is preferred over terminal sterilization because published data on marker stability of this specific formulation after 121°C for 15 min are limited; if terminal sterilization is used, a pre-validation study against USP <788> particulate matter and USP <85> bacterial endotoxins is required. Aseptic filling into 10 mL or 50 mL amber type I glass vials is conducted under grade A laminar flow, with line speed not exceeding 120 vials/min to avoid foaming; the maximum hold time between bioburden filtration and sterile fill is 4 h at 2–8°C. Compliance follows Ph. Eur. 5.1.1 methods of preparation of sterile products and 21 CFR 211.113 control of microbiological contamination. The terminal finished product type is an injectable solution for intramuscular or subcutaneous administration. The solution should not be combined with strong oxidizing agents or cationic preservatives due to potential complexation, and pH should remain above 5.0 to avoid precipitation.

When Companion Animal Geriatric Capsules Require Low-Moisture Dry Granulation

Low-moisture dry granulation is selected for companion animal geriatric capsules because the powder becomes adhesive at residual moisture above 8.0%. The addition ratio is 40–60% w/w in the dry granule fill, with microcrystalline cellulose, dibasic calcium phosphate dihydrate, and 1.0% magnesium stearate as the lubricant. Granulation is conducted on a roller compactor at roll force 8–12 kN/cm and gap 1.5–2.0 mm; the ribbons are milled through a 0.8–1.25 mm screen to obtain a granule fraction with bulk density 0.55–0.70 g/mL. Final flow is measured by Ph. Eur. 2.9.36 powder flow and should not exceed 25 s/100 g through a 10 mm orifice. Capsule filling is done on a semiautomatic 3000 capsules/h machine into size 0 hydroxypropyl methylcellulose capsules, with weight uniformity controlled by USP <905>. The terminal finished product type is oral capsules or direct-compressed tablets for geriatric companion animals.

Where Leaching Losses in Aqua Feed Coating Exceed 15%

In aquaculture feed manufacturing, the powder is incorporated after extrusion to reduce leaching losses that occur when botanical fine particles are included in the raw extrusion mix. The addition ratio is 0.2–0.5 wt% of finished feed, prepared as a 1:5 dispersion in a non-aqueous carrier of fish oil and soy lecithin. The downstream process uses a vacuum coating chamber operated at –0.06 MPa for 12 min to draw the dispersion into the porous pellet structure; this is followed by a post-coating air drying step at 35°C for 30 min to fix the oil film and reduce surface stickiness. The terminal finished product types are coated extruded pellets and aqua medicated premix. Compliance is handled under ISO 22000:2018 hazard analysis and FAMI-QS 6.0; species-specific feed safety limits require alignment with the destination market’s medicated feed regulations. Published data for this specific botanical configuration in aqua feed is limited, so each batch is supported by a physical stability and leaching screening protocol rather than a fixed efficacy dossier.